FDA again rejects AbbVie's continuous infusion therapy for Parkinson's
The FDA has rejected a new Parkinson’s drug from AbbVie for a second time.
Regulators turned away ABBV-951, a 24-hour infusion therapy to treat advanced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
